Cargando…

Associations between paracetamol (acetaminophen) intake between 18 and 32 weeks gestation and neurocognitive outcomes in the child: A longitudinal cohort study

BACKGROUND: The majority of epidemiological studies concerning possible adverse effects of paracetamol (acetaminophen) in pregnancy have been focussed on childhood asthma. Initial results of a robust association have been confirmed in several studies. Recently, a few cohort studies have looked at pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Golding, Jean, Gregory, Steven, Clark, Rosie, Ellis, Genette, Iles‐Caven, Yasmin, Northstone, Kate
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217049/
https://www.ncbi.nlm.nih.gov/pubmed/31523834
http://dx.doi.org/10.1111/ppe.12582
_version_ 1783532538177781760
author Golding, Jean
Gregory, Steven
Clark, Rosie
Ellis, Genette
Iles‐Caven, Yasmin
Northstone, Kate
author_facet Golding, Jean
Gregory, Steven
Clark, Rosie
Ellis, Genette
Iles‐Caven, Yasmin
Northstone, Kate
author_sort Golding, Jean
collection PubMed
description BACKGROUND: The majority of epidemiological studies concerning possible adverse effects of paracetamol (acetaminophen) in pregnancy have been focussed on childhood asthma. Initial results of a robust association have been confirmed in several studies. Recently, a few cohort studies have looked at particular neurocognitive outcomes, and several have implicated hyperactivity. OBJECTIVES: In order to confirm these findings, further information and results are required. Here, we assess whether paracetamol intake between 18 and 32 weeks gestation is associated with childhood behavioural and cognitive outcomes using a large population. METHODS: Data collected by the Avon Longitudinal Study of Parents and Children (ALSPAC) at 32 weeks gestation and referring to the period from 18 to 32 weeks, identified 43.9% of women having taken paracetamol. We used an exposome analysis first to determine the background factors associated with pregnant women taking the drug, and then allowed for those factors to assess associations with child outcomes (measured using regression analyses). RESULTS: We identified 15 variables independently associated with taking paracetamol in this time period, which were used as potential confounders. Of the 135 neurocognitive variables considered, adjusting for the likelihood of false discovery, we identified 56 outcomes for adjusted analyses. Adjustment identified 12 showing independent associations with paracetamol use at P < .05, four of which were at P < .0001 (all related to child behaviours reported by the mother at 42 and 47 months; eg conduct problems: adjusted mean score + 0.22 (95% confidence interval 0.10, 0.33)). There were few associations with behavioural or neurocognitive outcomes after age 7‐8 years, whether reported by the mother or the teacher. CONCLUSIONS: If paracetamol use in mid‐to‐late pregnancy has an adverse effect on child neurocognitive outcome, it appears to mainly relate to the pre‐school period. It is important that these results be tested using other datasets or methodologies before assuming that they are causal.
format Online
Article
Text
id pubmed-7217049
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-72170492020-05-13 Associations between paracetamol (acetaminophen) intake between 18 and 32 weeks gestation and neurocognitive outcomes in the child: A longitudinal cohort study Golding, Jean Gregory, Steven Clark, Rosie Ellis, Genette Iles‐Caven, Yasmin Northstone, Kate Paediatr Perinat Epidemiol Special Issue: Acetaminophen‐neurodevelopment BACKGROUND: The majority of epidemiological studies concerning possible adverse effects of paracetamol (acetaminophen) in pregnancy have been focussed on childhood asthma. Initial results of a robust association have been confirmed in several studies. Recently, a few cohort studies have looked at particular neurocognitive outcomes, and several have implicated hyperactivity. OBJECTIVES: In order to confirm these findings, further information and results are required. Here, we assess whether paracetamol intake between 18 and 32 weeks gestation is associated with childhood behavioural and cognitive outcomes using a large population. METHODS: Data collected by the Avon Longitudinal Study of Parents and Children (ALSPAC) at 32 weeks gestation and referring to the period from 18 to 32 weeks, identified 43.9% of women having taken paracetamol. We used an exposome analysis first to determine the background factors associated with pregnant women taking the drug, and then allowed for those factors to assess associations with child outcomes (measured using regression analyses). RESULTS: We identified 15 variables independently associated with taking paracetamol in this time period, which were used as potential confounders. Of the 135 neurocognitive variables considered, adjusting for the likelihood of false discovery, we identified 56 outcomes for adjusted analyses. Adjustment identified 12 showing independent associations with paracetamol use at P < .05, four of which were at P < .0001 (all related to child behaviours reported by the mother at 42 and 47 months; eg conduct problems: adjusted mean score + 0.22 (95% confidence interval 0.10, 0.33)). There were few associations with behavioural or neurocognitive outcomes after age 7‐8 years, whether reported by the mother or the teacher. CONCLUSIONS: If paracetamol use in mid‐to‐late pregnancy has an adverse effect on child neurocognitive outcome, it appears to mainly relate to the pre‐school period. It is important that these results be tested using other datasets or methodologies before assuming that they are causal. John Wiley and Sons Inc. 2019-09-15 2020-05 /pmc/articles/PMC7217049/ /pubmed/31523834 http://dx.doi.org/10.1111/ppe.12582 Text en © 2019 The Authors. Paediatric and Perinatal Epidemiology published by John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Special Issue: Acetaminophen‐neurodevelopment
Golding, Jean
Gregory, Steven
Clark, Rosie
Ellis, Genette
Iles‐Caven, Yasmin
Northstone, Kate
Associations between paracetamol (acetaminophen) intake between 18 and 32 weeks gestation and neurocognitive outcomes in the child: A longitudinal cohort study
title Associations between paracetamol (acetaminophen) intake between 18 and 32 weeks gestation and neurocognitive outcomes in the child: A longitudinal cohort study
title_full Associations between paracetamol (acetaminophen) intake between 18 and 32 weeks gestation and neurocognitive outcomes in the child: A longitudinal cohort study
title_fullStr Associations between paracetamol (acetaminophen) intake between 18 and 32 weeks gestation and neurocognitive outcomes in the child: A longitudinal cohort study
title_full_unstemmed Associations between paracetamol (acetaminophen) intake between 18 and 32 weeks gestation and neurocognitive outcomes in the child: A longitudinal cohort study
title_short Associations between paracetamol (acetaminophen) intake between 18 and 32 weeks gestation and neurocognitive outcomes in the child: A longitudinal cohort study
title_sort associations between paracetamol (acetaminophen) intake between 18 and 32 weeks gestation and neurocognitive outcomes in the child: a longitudinal cohort study
topic Special Issue: Acetaminophen‐neurodevelopment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217049/
https://www.ncbi.nlm.nih.gov/pubmed/31523834
http://dx.doi.org/10.1111/ppe.12582
work_keys_str_mv AT goldingjean associationsbetweenparacetamolacetaminophenintakebetween18and32weeksgestationandneurocognitiveoutcomesinthechildalongitudinalcohortstudy
AT gregorysteven associationsbetweenparacetamolacetaminophenintakebetween18and32weeksgestationandneurocognitiveoutcomesinthechildalongitudinalcohortstudy
AT clarkrosie associationsbetweenparacetamolacetaminophenintakebetween18and32weeksgestationandneurocognitiveoutcomesinthechildalongitudinalcohortstudy
AT ellisgenette associationsbetweenparacetamolacetaminophenintakebetween18and32weeksgestationandneurocognitiveoutcomesinthechildalongitudinalcohortstudy
AT ilescavenyasmin associationsbetweenparacetamolacetaminophenintakebetween18and32weeksgestationandneurocognitiveoutcomesinthechildalongitudinalcohortstudy
AT northstonekate associationsbetweenparacetamolacetaminophenintakebetween18and32weeksgestationandneurocognitiveoutcomesinthechildalongitudinalcohortstudy